Bristol-Myers Squibb Co
BMY
NYSE
Pharmaceuticals
$65.47
USD
-2.14 (-3.17%)
At close: Aug 20, 2026, 4:00 PM EDT
Market Cap $131.92B
Volume 9.4M
Revenue
$49.19B
TTM
+3.1%
YoY
Gross Margin
70%
TTM
-0.2%
YoY
Net Income
$9.27B
TTM
+83.1%
YoY
Operating Cash Flow
$12.78B
TTM
-19.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 12,269.0 | 12,222.0 | 12,502.0 | 11,489.0 | 12,973.0 |
YoY Growth | +0.6% | +2.8% | +1.3% | +2.6% | +5.7% |
Cost of Revenue | 3,372.0 | 3,435.0 | 4,097.0 | 3,421.0 | 3,726.0 |
Gross Profit | 8,897.0 | 8,787.0 | 8,405.0 | 8,068.0 | 9,247.0 |
Selling, General & Administrative | 1,713.0 | 1,789.0 | 2,181.0 | 1,617.0 | 1,826.0 |
Other Operating Expenses | 1,508.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 6,631.0 | 5,781.0 | 6,986.0 | 4,797.0 | 5,222.0 |
Operating Income | 2,266.0 | 3,006.0 | 1,419.0 | 3,271.0 | 4,025.0 |
EBITDA | 4,785.0 | 4,017.0 | 2,396.0 | 3,865.0 | 4,619.0 |
Other Income / Expense | -147.0 | 108.0 | 51.0 | -31.0 | 367.0 |
Total Other Income / Expense | -493.0 | 108.0 | 51.0 | -31.0 | 61.0 |
Income Before Income Taxes | 1,773.0 | 3,114.0 | 1,470.0 | 3,240.0 | 4,086.0 |
Income Taxes | 460.0 | 919.0 | 384.0 | 561.0 | 770.0 |
Net Income | 1,313.0 | 2,195.0 | 1,085.0 | 2,678.0 | 3,316.0 |
Consolidated Net Income / Loss | 1,313.0 | 2,195.0 | 1,086.0 | 2,679.0 | 3,316.0 |
Net Income Attributable to Common Shareholders | 1,310.0 | 2,201.0 | 1,087.0 | 2,677.0 | 3,317.0 |
Basic EPS | $0.64 | $1.08 | $0.53 | $1.31 | $1.62 |
Diluted EPS | $0.64 | $1.08 | $0.53 | $1.31 | $1.62 |
Basic Shares Outstanding | 2,035.0M | 2,036.0M | 2,034.0M | 2,038.0M | 2,042.0M |
Diluted Shares Outstanding | 2,038.0M | 2,039.0M | 2,039.0M | 2,047.0M | 2,048.0M |